Apolipoprotein E and Coronary Disease: A Puzzling Paradox

DOI: 10.1371/journal.pmed.0030258

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Mahley RW, Rall SC (2000) Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1: 507–537.
[2]	Davignon J, Gregg RE, Sing CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8: 1–21.
[3]	Curtiss LK (2000) ApoE in atherosclerosis: A protein with multiple hats. Arterioscler Thromb Vasc Biol 20: 1852–1853.
[4]	Tangirala RK, Pratico D, FitzGerald GA, Chun S, Tsukamoto K, et al. (2001) Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem 276: 261–266.
[5]	Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, et al. (1995) Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 96: 2170–2179.
[6]	Thorngate FE, Rudel LL, Walzem RL, Williams DL (2000) Low levels of extrahepatic nonmacrophage ApoE inhibit atherosclerosis without correcting hypercholesterolemia in ApoE-deficient mice. Comments. Arterioscler Thromb Vasc Biol 20: 1939–1945.
[7]	Mazzone T (1996) Apolipoprotein E secretion by macrophages: Its potential physiological functions. Curr Opin Lipidol 7: 303–307.
[8]	Kelly ME, Clay MA, Mistry MJ, Hsieh-Li HM, Harmony JA (1994) Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: Production of interleukin 2 with reduced biological activity. Cell Immunol 159: 124–139.
[9]	Swertfeger DK, Hui DY (2001) Apolipoprotein E: A cholesterol transport protein with lipid transport-independent cell signaling properties. Front Biosci 6: D526–D535.
[10]	Tangirala RK, Pratico D, FitzGerald GA, Chun S, Tsukamoto K, et al. (2001) Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem 276: 261–266.
[11]	van Oosten M, Rensen PC, van Amersfoort ES, Van Eck M, Van Dam AM, et al. (2001) Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. J Biol Chem 276: 8820–8824.
[12]	Ali K, Middleton M, Pure E, Rader DJ (2005) Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ Res 97: 922–927.
[13]	Mooijaart SP, Berbee JFP, van Heemst D, Havakes LM, de Craen AJM, et al. (2006) ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med 3(6): e176. doi: 10.1371/journal.pmed.0030176.
[14]	Twickler T, Dallinga-Thie GM, Chapman MJ, Cohn JS (2005) Remnant lipoproteins and atherosclerosis. Curr Atheroscler Rep 7: 140–147.
[15]	van den Elzen P, Garg S, Leon L, Brigl M, Leadbetter EA, et al. (2005) Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437: 906–910.
[16]	Rader DJ (2000) Inflammatory markers of coronary risk. N Engl J Med 343: 1179–1182.
[17]	Lyngdorf LG, Gregersen S, Daugherty A, Falk E (2003) Paradoxical reduction of atherosclerosis in apoE-deficient mice with obesity-related type 2 diabetes. Cardiovasc Res 59: 854–862.
[18]	Schreyer SA, Vick C, Lystig TC, Mystkowski P, LeBoeuf RC (2002) LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice. Am J Physiol Endocrinol Metab 282: E207–E214.
[19]	Chiba T, Nakazawa T, Yui K, Kaneko E, Shimokado K (2003) VLDL induces adipocyte differentiation in ApoE-dependent manner. Arterioscler Thromb Vasc Biol 23: 1423–1429.

Full-Text